European Research Council

Foresight Institute Announces 2023 Feynman Prize Winners

Retrieved on: 
Sunday, October 29, 2023

SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies. Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies. Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.

Key Points: 
  • SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies.
  • Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies.
  • Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.
  • Foresight Institute also bestows the Distinguished Student Award, spotlighting an upcoming individual for their exceptional work in advancing nanotechnology development and understanding.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Thursday, September 28, 2023

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Key Points: 
  • Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Thursday, September 28, 2023

ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

Key Points: 
  • ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

The Consortium for the protection of Barolo Barbaresco Alba Langhe e Dogliani presents Barolo en primeur in the United States

Retrieved on: 
Thursday, September 7, 2023

The evenings will consist of two masterclasses conducted by Matteo Ascheri, president of the Consortium for the protection of Barolo Barbaresco Alba Langhe e Dogliani to the Ordine dei Cavalieri del Tartufo e dei Vini di Alba of the respective U.S. delegations.

Key Points: 
  • The evenings will consist of two masterclasses conducted by Matteo Ascheri, president of the Consortium for the protection of Barolo Barbaresco Alba Langhe e Dogliani to the Ordine dei Cavalieri del Tartufo e dei Vini di Alba of the respective U.S. delegations.
  • The territories involved in the activity are in order of tasting: Verduno, La Morra and Grinzane, Roddi and Castiglione, Barolo, Novello and Monforte, and Serralunga.
  • This activity, together with Barolo en primeur 2022 is a social responsibility initiative promoted by the CRC Foundation, in collaboration with the Consortium for the protection of Barolo Barbaresco Alba Langhe and Dogliani: a charity competition to support socially useful projects, both in Italy and abroad.
  • The aim of this activity and another project, which is the Barolo en primeur auction, in collaboration with the CRC Foundation Cuneo and Christie's, is to highlight the potential of en primeur tastings to raise awareness, appreciation and promotion of both Barolo and Barbaresco.

Barolo and Barbaresco fly to China for Vinitaly China Roadshow

Retrieved on: 
Tuesday, September 5, 2023

The activities in China include the participation of more than 85 Barolo and Barbaresco companies in various industry fairs and the organization of several workshops.

Key Points: 
  • The activities in China include the participation of more than 85 Barolo and Barbaresco companies in various industry fairs and the organization of several workshops.
  • From Sept. 11 to 15, 2023 as part of Vinitaly China Roadshow, the Veronafiere-branded event, Barolo and Barbaresco will be the stars of the days on a taste itinerary between Beijing, Changsha and Hangzhou.
  • The last event will be in Hangzhou, one of the most important cities in coastal China at 1366 Qianjiang Road, Shangcheng District.
  • The purpose is to educate wine professionals in emerging cities and create a tasting area with food & Barolo and Barbaresco pairing tastings.

GIFS researcher supports international team effort to sequence earliest domesticated wheat genome

Retrieved on: 
Wednesday, August 30, 2023

More than two dozen scientists have contributed to a project that that has sequenced and characterized genomes of wild and domesticated einkorn, the world’s first domesticated wheat species.

Key Points: 
  • More than two dozen scientists have contributed to a project that that has sequenced and characterized genomes of wild and domesticated einkorn, the world’s first domesticated wheat species.
  • “Though significant advances have been made in wheat species genomics, the species Triticum monococum (einkorn), representing the earliest domesticated wheat, was not defined yet,” said Datla.
  • “The insights gained from genome sequencing wild and domesticated accessions allow us to reconstruct the origin and evolution of einkorn,” said Datla.
  • In 2020, a team, led by USask’s Dr. Curtis Pozniak (PhD), sequenced the genomes for 15 different wheat varieties.

BIAL Award in Biomedicine worth 300,000 Euros

Retrieved on: 
Wednesday, April 26, 2023

TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June. With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.

Key Points: 
  • TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June.
  • With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.
  • Candidates for this international award may be nominated by members of the Jury, members of the Scientific Board of the BIAL Foundation, previous BIAL Award winners, Scientific Societies, Boards or Deans of Medical Faculties, Heads of leading research institutes, and Boards or Heads of prestigious Academies.
  • The BIAL Award in Biomedicine takes place biannually, in odd-numbered years, alternating with the Prémio BIAL de Medicina Clínica.

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Retrieved on: 
Thursday, January 19, 2023

BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.

Key Points: 
  • Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.
  • This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa.
  • The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call.
  • Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics.

Tissue Dynamics Unveiling DynamiX® a Bionic Multi Organ-on-Chip Bioanalyzer

Retrieved on: 
Thursday, January 5, 2023

REHOVOT, Israel, Jan. 5, 2023 /PRNewswire/ -- Drug development is a Sisyphean endeavor that takes over 10 years of work, and costs over $2.6B to bring a single drug to the market. Despite decades of work, the field is still heavily reliant on animal models, like mice, that have different metabolism, genetics and physiology from humans. These differences lead to many clinical failures. In fact, more than 88% of clinical studies fail due to unknown adverse events or misunderstood mechanism of action.

Key Points: 
  • Tissue Dynamic's new platform is a breakthrough in animal-free drug development.
  • Despite decades of work, the field is still heavily reliant on animal models, like mice, that have different metabolism, genetics and physiology from humans.
  • However, the design accepts a wide variety of organ models, including organoids, spheroids, and tissue microsections in 384 well plate format.
  • Applications range from disease modeling, hit identification to target validation, extending safety and efficacy evaluations far beyond current methodologies.

RCSI research explains how our body clock influences vaccine responses

Retrieved on: 
Tuesday, December 6, 2022

DUBLIN, Dec. 6, 2022 /PRNewswire/ -- Research by RCSI University of Medicine and Health Sciences has provided new insights into the mechanism behind how our circadian 24-hour body clock influences our immune response to vaccines, depending on the time of day.

Key Points: 
  • DUBLIN, Dec. 6, 2022 /PRNewswire/ -- Research by RCSI University of Medicine and Health Sciences has provided new insights into the mechanism behind how our circadian 24-hour body clock influences our immune response to vaccines, depending on the time of day.
  • This research has uncovered that our circadian clock is changing the shape of mitochondria within dendritic cells.
  • We can apply this understanding in vaccine development to ensure we receive the maximum benefits from vaccination."
  • Further support was provided by a Conacyt grant, a SFI Investigator Award and a European Research Council Consolidator Award.